Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin versus empagliflozin added to metformin in type 2 diabetes
IRCT20191231045959N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sitagliptin and empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Blood glucose, Lipid profile and 3 more. Started Nov 2019; status: completed.
02
Drugs
sitagliptinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20191231045959N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191231045959N1.